SKF 105685
Latest Information Update: 22 Mar 2000
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Antipsoriatics; Antirheumatics; Spiro compounds
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
- Discontinued Autoimmune disorders; Hypercholesterolaemia; Transplant rejection
Most Recent Events
- 22 Mar 2000 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
- 26 Apr 1996 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)
- 26 Apr 1996 Discontinued-Preclinical for Transplant rejection in USA (Unknown route)